Dovobet® (Calcipotriol and Betamethasone Dipropionate) - A - Detailing from Skin Therapy Letter

 

Dovobet® (Calcipotriol and Betamethasone Dipropionate)

 

 

  Content:

SIDE EFFECTS, SAFETY AND RISKS

 

 

Side Effects

  • Because Dovobet is a combination drug, the frequency of side effects reported is less than would be expected if using each compound on its own: for example, the anti-inflammatory action of the corticosteroid (betamethasone dipropionate) minimizes the irritation often reported when using calcipotriol alone.
  • Approximately 5% to 10% of patients report itching.
  • In a study of over 1000 patients, 9.9% reported lesional or perilesional adverse reactions.
  • No changes have been reported in serum calcium.

Risks

  • The recommended treatment period is 4 weeks. In this period the majority of patients will benefit satisfactorily. However some patients will require longer treatment than 4 weeks which should be based on physicians‘ assessment of the benefit/risks of continuing the treatment regimen, as prolonged use of steroids can interfere with collagen production and vascular stability producing skin atrophy and purpura.
  • Dovobet should not be used concurrently with other corticosteroid creams or ointments.

Monitoring

  • Monitor for clinical improvement in the skin as well as for side effects such as atrophy, purpura, perioral dermatitis, rosacea and other side effects of topical steroids.
  • Monitoring of serum calcium is not necessary when the recommended quantities are used.

Next:   Cost of Treatment